Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NVS
STRONG BUYNovartis AG · Healthcare · Switzerland · $294.6B · Avg Vol: $326M/d
91
StockRankGet insider-trade alerts
Q
73
V
47
M
69
P/E (TTM)
23.4x
ROE
30.3%
D/E
1.2x
Dividend %
3.0%
Loading 1Y...
PRICE (1Y)+2.0%
SMA 50SMA 200
Close
$156.11
RSI (14)
48.1
52W High
$165.43
From 52W High
0.9%
SCORE BREAKDOWN
Quality
73
ROIC
20.2%91.5
ROE
30.3%94.0
GP/Assets
38.3%78.6
Op. Margin
34.6%95.0
FCF/Assets
13.5%92.1
Piotroski
376.1
Int. Cover
12.2x64.2
D/E Ratio
1.17x12.0
Current Ratio
0.86x7.4
Value
47
P/E (TTM)
23.4x50.8
EV/EBITDA
14.6x46.8
P/FCF
19.7x60.3
P/B
7.7x15.8
P/S
5.2x41.2
Div Yield
3.0%68.2
Momentum
69
52W High %
94%93.3
RS 6M
2%74.5
SMA 50/200
1.06x75.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+48%53.7
Q Growth
-19%23.8
FUNDAMENTALS
Market Cap
$294.6B
P/E (Forward)
15.8x
Gross Margin
75.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NVS | Novartis AG(you) | $294.6B | 91 | STRONG BUY |
| MRK | Merck & Co., Inc. | $323.7B | 92 | STRONG BUY |
| RO.SW | Roche Holding AG | $336.1B | 92 | STRONG BUY |
| NVON.MX | Novo Nordisk A/S | $212.5B | 91 | STRONG BUY |
| AMG.DE | Amgen Inc. | $194.3B | 90 | STRONG BUY |
| AZN | AstraZeneca PLC | $262.5B | 83 | STRONG BUY |
| 4AB.DE | AbbVie Inc. | $438.1B | 87 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $160.5B | 92 | STRONG BUY |
| JNJ.MX | Johnson & Johnson | $588.5B | 88 | STRONG BUY |
| PFE.DE | Pfizer Inc. | $138.0B | 94 | STRONG BUY |
Peer medians: ROE 2.0% · P/E 23.4x · Gross margin 50.0%